Based on the results of this study, we suggest that for BCS class III drug with high < em class= " a-plus-plus " > F < /em > < sub class= " a-plus-plus " > a < /sub > (about & gt;80 %), the biowaiver should extend to rapid dissolution ( < em class= " a-plus-plus " > T < /em > < sub class= " a-plus-plus " > 85 % < /sub > = 30 min), and 30 %..."> Based on the results of this study, we suggest that for BCS class III drug with high < em class= " a-plus-plus " > F < /em > < sub class= " a-plus-plus " > a < /sub > (about & gt;80 %), the biowaiver should extend to rapid dissolution ( < em class= " a-plus-plus " > T < /em > < sub class= " a-plus-plus " > 85 % < /sub > = 30 min), and 30 %..." /> Based on the results of this study, we suggest that for BCS class III drug with high < em class= " a-plus-plus " > F < /em > < sub class= " a-plus-plus " > a < /sub > (about & gt;80 %), the biowaiver should extend to rapid dissolution ( < em class= " a-plus-plus " > T < /em > < sub class= " a-plus-plus " > 85 % < /sub > = 30 min), and 30 %..." />